Ting Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ting Li has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Azza Abdelkarim
Safety Evaluation and Risk Management, GSK, Warsaw, Poland
1 shared publication- Cui Xiong
R&D, GSK, Shanghai, China
1 shared publication - Daiming Fan
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an, China
1 shared publication Danrong Yang
Shanghai 6th People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publicationHanqing Guo
1 shared publicationJie Song
R&D, GSK, Shanghai, China
1 shared publication
Latest Publications
- 12 March 2024
- Published by Elsevier in Food Chemistry
- Vol. 447, 138969
Direct infusion–multiple reaction monitoring cubed (DI–MRM3) enables widely targeted bi-omics of Colla Corii Asini (Chinese name: Ejiao)
- 12 March 2024
- Published by Elsevier in Food Chemistry
- Vol. 447, 138969
Direct infusion–multiple reaction monitoring cubed (DI–MRM3) enables widely targeted bi-omics of Colla Corii Asini (Chinese name: Ejiao)
- Open Access
- 8 February 2024
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 10 (3) , 00750-2023
Efficacy and safety of mepolizumab in a Chinese population with severe asthma: a phase III, randomised, double-blind, placebo-controlled trial
Background: In China, the prevalence of severe asthma with eosinophilic phenotype is rising, yet treatment options are limited. Mepolizumab is the first targeted biologic therapy for eosinophilic-driven disease in China. This study (clinicaltrials.gov identifierNCT03562195) evaluated efficacy and safety of mepolizumab in Chinese patients with severe asthma.Methods: The phase III, multicentre, randomised, placebo-controlled, double-blind, parallel-group study enrolled patients aged ≥12 years with severe asthma, with two or more exacerbations in the previous year, and on inhaled corticosteroids plus at least one controller medication. Following a 1–4-week run-in, patients were randomised 1:1 to mepolizumab 100 mg or placebo subcutaneously every 4 weeks for 52 weeks. The primary end-point was annualised rate of clinically significant exacerbations (CSEs) through week 52. Secondary end-points were time to first CSE, frequency of CSEs requiring hospitalisation/emergency department visits or hospitalisation over 52 weeks, mean change in St George's Respiratory Questionnaire (SGRQ) total score and pre-bronchodilator forced expiratory volume in 1 s (FEV1) at week 52; safety was evaluated.Results: The modified intention-to-treat population included 300 patients. At week 52 with mepolizumabversusplacebo, annualised rate of CSEs was 65% lower (0.45versus1.31 events per year; rate ratio 0.35, 95% CI 0.24–0.50; p1increased (p=0.006). Incidence of adverse events was similar between treatment groups.Conclusion: Mepolizumab provided clinical benefits to patients with severe asthma in China and showed a favourable benefit–risk profile.
- 8 February 2024
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 10 (3) , 00750-2023
Open AccessEfficacy and safety of mepolizumab in a Chinese population with severe asthma: a phase III, randomised, double-blind, placebo-controlled trial
Background: In China, the prevalence of severe asthma with eosinophilic phenotype is rising, yet treatment options are limited. Mepolizumab is the first targeted biologic therapy for eosinophilic-driven disease in China. This study (clinicaltrials.gov identifierNCT03562195) evaluated efficacy and safety of mepolizumab in Chinese patients with severe asthma.Methods: The phase III, multicentre, randomised, placebo-controlled, double-blind, parallel-group study enrolled patients aged ≥12 years with severe asthma, with two or more exacerbations in the previous year, and on inhaled corticosteroids plus at least one controller medication. Following a 1–4-week run-in, patients were randomised 1:1 to mepolizumab 100 mg or placebo subcutaneously every 4 weeks for 52 weeks. The primary end-point was annualised rate of clinically significant exacerbations (CSEs) through week 52. Secondary end-points were time to first CSE, frequency of CSEs requiring hospitalisation/emergency department visits or hospitalisation over 52 weeks, mean change in St George's Respiratory Questionnaire (SGRQ) total score and pre-bronchodilator forced expiratory volume in 1 s (FEV1) at week 52; safety was evaluated.Results: The modified intention-to-treat population included 300 patients. At week 52 with mepolizumabversusplacebo, annualised rate of CSEs was 65% lower (0.45versus1.31 events per year; rate ratio 0.35, 95% CI 0.24–0.50; p1increased (p=0.006). Incidence of adverse events was similar between treatment groups.Conclusion: Mepolizumab provided clinical benefits to patients with severe asthma in China and showed a favourable benefit–risk profile.
- 1 May 2020
- Published by Elsevier in Gastroenterology
- Vol. 158 (6)
Sa1174 CYCLOPHILIN B PROMOTES COLON CANCER PROLIFERATION AND METASTASIS THROUGH STAT3 ACTIVATION AND COLLAGEN HYDROXYLATION.
- 1 May 2020
- Published by Elsevier in Gastroenterology
- Vol. 158 (6)
Sa1174 CYCLOPHILIN B PROMOTES COLON CANCER PROLIFERATION AND METASTASIS THROUGH STAT3 ACTIVATION AND COLLAGEN HYDROXYLATION.